Literature DB >> 16941718

Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: a case-time-control study.

Dorte Kjaer1, Erzsébet Horvath-Puhó, Jakob Christensen, Mogens Vestergaard, Andrew E Czeizel, Henrik Toft Sørensen, Jørn Olsen.   

Abstract

PURPOSE: Case-control studies are often used to examine putative teratogenic drug effects during organogenesis but these studies are subject to confounding by indication, recall, and participation bias. The case-time-control approach is less susceptible to these sources of bias. We studied congenital abnormalities following exposure to phenytoin, phenobarbital, and diazepam in early pregnancy, i.e., second and third month, compared to mid-pregnancy, i.e., fifth and sixth month of pregnancy.
METHODS: We analyzed data from the Hungarian Case-Control Surveillance of Congenital Abnormalities (1980-1996) in a case-time-control study.
RESULTS: The study included 22 843 children with congenital abnormalities (cases) and 38 151 children with no abnormalities (controls). Overall, odds ratio (OR) for congenital abnormalities after exposure to one of the three drugs in early pregnancy was 1.2 (95% confidence interval (CI): 1.0-1.4). Among children exposed to phenytoin OR for congenital abnormalities was 3.7 (95%CI: 0.3-49.6), for children exposed to phenobarbital the OR was 1.1 (95%CI 0.7-1.7), and for diazepam, OR for congenital abnormalities was 1.2 (95%CI: 1.0-1.4).
CONCLUSIONS: The associations we found between the drugs examined and congenital abnormalities were either only borderline significant or not statistically significant. The case-time-control study provides an interesting way of using existing case-control data to study rare side effect of drugs taken during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16941718     DOI: 10.1002/pds.1288

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  9 in total

Review 1.  Risk factors for cryptorchidism.

Authors:  Jason K Gurney; Katherine A McGlynn; James Stanley; Tony Merriman; Virginia Signal; Caroline Shaw; Richard Edwards; Lorenzo Richiardi; John Hutson; Diana Sarfati
Journal:  Nat Rev Urol       Date:  2017-06-27       Impact factor: 14.432

Review 2.  Antiepileptic drugs and pregnancy outcomes.

Authors:  Bogdan J Wlodarczyk; Ana M Palacios; Timothy M George; Richard H Finnell
Journal:  Am J Med Genet A       Date:  2012-06-18       Impact factor: 2.802

Review 3.  Managing epilepsy in women of childbearing age.

Authors:  Pamela M Crawford
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 4.  Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest?

Authors:  Page B Pennell
Journal:  Epilepsia       Date:  2008-12       Impact factor: 5.864

5.  Pregnancy and epilepsy:update on pregnancy registries.

Authors:  Kaarkuzhali B Krishnamurthy
Journal:  Curr Treat Options Neurol       Date:  2008-07       Impact factor: 3.598

6.  Management of pregnancy in Crigler Najjar syndrome type 2.

Authors:  Alisha Nitin Chaubal; Ruchir Patel; Dhaval Choksi; Kaivan Shah; Meghraj Ingle; Prabha Sawant
Journal:  World J Hepatol       Date:  2016-04-18

7.  Interpretation of controversial teratogenic findings of drugs such as phenobarbital.

Authors:  Andrew E Czeizel; Istvan Dudás; Ferenc Bánhidy
Journal:  ISRN Obstet Gynecol       Date:  2011-09-04

8.  FTIR Microspectroscopy Reveals Chemical Changes in Mice Fetus Following Phenobarbital Administration.

Authors:  Azadeh Ashtarinezhad; Ataollah Panahyab; Baharak Mohamadzadehasl; Hossein Vatanpour; Farshad H Shirazi
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

9.  First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort study.

Authors:  Lu Ban; Joe West; Jack E Gibson; Linda Fiaschi; Rachel Sokal; Pat Doyle; Richard Hubbard; Liam Smeeth; Laila J Tata
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.